Sharechat Logo

Of Bulls & Bears

Friday 1st September 2000

Text too small?

Genesis' profitable option

Investors are prostrating themselves before brokers this week, pleading for some shares in Genesis Research and Development Corporation, New Zealand's first pure biotechnology share market float. The company has a range of gene-based products and systems that have a good chance of producing commercially viable drugs to treat numerous human and plant diseases. Shares are being offered on both sides of the Tasman at $6 a piece and many investors are convinced they will go higher once trading begins later this month. One indication of the share's popularity is the use of a shares-instead-of-fees deal that has been in vogue for many dotcom listings in the US. The Genesis prospectus shows it has granted a company called Executive Search International an option to buy 20,000 shares at $2.75 "in consideration for Executive Search International Ltd providing professional introduction and appointment services in relation to the appointment of a consultant to the company." At this price, Executive Search is guaranteed to more than double its money when Genesis floats and potentially earn far more.

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Mandatory farm plans scorned as 'tick box' exercises
Kiwi dollar firms on weak US retail data, capped by rate-cut expectations
17th October 2019 Morning Report
SkyCity hoses down union claims over potential job losses
OPINION: Fair Payment Agreements and 'swallowing vomit' - the lot of the CTU
MARKET CLOSE: NZ shares gain; Restaurant Brands climbs on upbeat outlook
NZ dollar stalls after Bascand's rate cut comments
Bascand says RBNZ will consider changing bank capital proposals
Affordable electricity key to decarbonisation - Genesis
Graeme Hart trims global packaging empire with US$615m asset sale

IRG See IRG research reports